Linqi Li

机构：Huaihua University, Central South University, Changsha Medical University, Yichun University, Tianjin Medical University Cancer Institute and Hospital, Changsha Central Hospital, Shaanxi University of Chinese Medicine, University of South China · ORCID：0000-0002-0976-6040

发表论文 18 篇 · 总被引 338 次 · h-index 7

代表论文

• Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry (2017 · Cancer Biology & Therapy · 被引 104)
• Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness (2021 · Theranostics · 被引 67)
• The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation (2021 · Theranostics · 被引 60)
• The diagnostic value of thyroglobulin in fine-needle aspiration of metastatic lymph nodes in patients with papillary thyroid cancer and its influential factors (2021 · Surgical Oncology · 被引 35)
• The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer (2018 · International Journal of Medical Sciences · 被引 29)
• JOSD1 promotes proliferation and chemoresistance of head and neck squamous cell carcinoma under the epigenetic regulation of BRD4 (2021 · Cancer Cell International · 被引 20)